Dr. Amarenco reports having received unrestricted grants from Pfizer, AstraZeneca, and Althera Pharmaceuticals, speaker's fees from Amgen and Viatris, and fees for serving on an advisory board or steering committee from Amgen, Novartis, and Kowa. No other potential conflict of interest relevant to this letter was reported.
New England Journal of Medicine 388(26):p 2488-2489, June 29, 2023.
